Q-omics provides the consensus-scored RNU6-19P profile across patient tissues and cancer cell-line models. RNU6-19P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNU6-19P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RNU6-19P RNA expression shows 8,666 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where RNU6-19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-19P survival associations across molecular data types. RNU6-19P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-19P RNA expression–survival associations across cancer types. High RNU6-19P expression shows unfavorable associations in KIRP, COAD, UCS, UVM and PCPG, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RNU6-19P RNA expression.
This table summarizes RNU6-19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-19P shows higher tumor expression in KIRC, KICH, BLCA, STAD and LUSC. The KIRC box plot shows higher RNU6-19P RNA expression in tumor versus normal tissue (log2 FC = +0.108, t-test p = .011).
This table shows molecular features associated with RNU6-19P in patient tissues and cancer cell lines. In patient samples, RNU6-19P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
